title: A Randomized Controlled Clinical Trial Investigating the Effect of Synbiotic Administration on Markers of Insulin Metabolism and Lipid Profiles in Overweight Type 2 Diabetic Patients with Coronary Heart Disease.
abstract: Objective:The current study was performed to evaluate the effects of synbiotic administration on metabolic profiles in overweight diabetic patients with coronary heart disease (CHD).Methods:This randomized, double-blind, placebo-controlled trial was done among 60 diabetic patients with CHD. Participants were randomly divided into 2 groups: group A (n=30) received synbiotic supplements containing 3 probiotic bacteria spicesLactobacillus acidophilus2×109,Lactobacillus casei2×109,Bifidobacterium bifidum2×109CFU/g plus 800 mg inulin and group B (n=30) received placebo for 12 weeks. Fasting blood samples were taken at baseline and after 12-week intervention to determine metabolic profiles.Results:After 12 weeks of intervention, patients who consumed synbiotic capsule had significantly decreased fasting plasma glucose (- 19.6±74.6 vs.+19.2±66.9 mg/dL, P=0.03), serum insulin concentrations (- 0.7±5.1 vs.+3.3±6.3 µIU/mL, P=0.01), the homeostasis model of assessment-estimated b cell function (- 3.4±19.5 vs.+11.5±21.0, P=0.006) and increased the quantitative insulin sensitivity check index (+ 0.002±0.01 vs.-0.01±0.02, P=0.03) compared with the placebo. In addition, changes in HLDL-cholesterol levels (+ 1.8±5.7 vs.-2.2±6.0 mg/dL, P=0.01) in supplemented patients were significantly different from those of patients in the placebo group.Conclusion:Synbiotic supplementation for 12 weeks among diabetic patients with CHD had beneficial effects on markers of insulin metabolism and HDL-cholesterol levels.
authors.affiliation: Faculty Member of Science Department, Science Faculty, Islamic Azad University, Tehran Central branch, Tehran, Iran.
authors.forename: M
authors.initials: M
authors.lastname: Tajabadi-Ebrahimi
authors.affiliation: Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.
authors.forename: N
authors.initials: N
authors.lastname: Sharifi
authors.affiliation: Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, I.R. Iran.
authors.forename: A
authors.initials: A
authors.lastname: Farrokhian
authors.affiliation: Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, I.R. Iran.
authors.forename: F
authors.initials: F
authors.lastname: Raygan
authors.affiliation: Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: F
authors.initials: F
authors.lastname: Karamali
authors.affiliation: Department of Infectious Disease, school of medicine, Kashan University of Medical Sciences, Kashan, I.R. Iran.
authors.forename: R
authors.initials: R
authors.lastname: Razzaghi
authors.affiliation: Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.
authors.forename: S
authors.initials: S
authors.lastname: Taheri
authors.affiliation: Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.
authors.forename: Z
authors.initials: Z
authors.lastname: Asemi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001644:Bifidobacterium; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000628:therapy; D048909:Diabetes Complications / Q000097:blood / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000628:therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood*; D007779:Lactobacillus acidophilus; D007780:Lacticaseibacillus casei; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D050177:Overweight / Q000097:blood / Q000209:etiology / Q000628:therapy; D019936:Probiotics / Q000008:administration & dosage*
chemical_list: D007328:Insulin; D008055:Lipids